E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness. Issue 3 (25th January 2019)
- Record Type:
- Journal Article
- Title:
- E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness. Issue 3 (25th January 2019)
- Main Title:
- E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness
- Authors:
- Cheng, Frank H. C.
Lin, Hon‐Yi
Hwang, Tzy‐Wei
Chen, Yin‐Chen
Huang, Rui‐Lan
Chang, Chia‐Bin
Yang, Weiqin
Lin, Ru‐Inn
Lin, Ching‐Wen
Chen, Gary C. W.
Mai, Shu‐Yuan
Lin, Jora M. J.
Chuang, Yu‐Ming
Chou, Jian‐Liang
Kuo, Li‐Wei
Li, Chin
Cheng, Alfred S. L.
Lai, Hung‐Cheng
Wu, Shu‐Fen
Tsai, Je‐Chiang
Chan, Michael W. Y. - Abstract:
- Abstract : Ovarian cancer is the most lethal cancer of the female reproductive system. In that regard, several epidemiological studies suggest that long‐term exposure to estrogen could increase ovarian cancer risk, although its precise role remains controversial. To decipher a mechanism for this, we previously generated a mathematical model of how estrogen‐mediated upregulation of the transcription factor, E2F6, upregulates the ovarian cancer stem/initiating cell marker, c‐Kit, by epigenetic silencing the tumor suppressor miR‐193a, and a competing endogenous (ceRNA) mechanism. In this study, we tested that previous mathematical model, showing that estrogen treatment of immortalized ovarian surface epithelial cells upregulated both E2F6 and c‐KIT, but downregulated miR‐193a . Luciferase assays further confirmed that microRNA‐193a targets both E2F6 and c‐Kit . Interestingly, ChIP‐PCR and bisulphite pyrosequencing showed that E2F6 also epigenetically suppresses miR‐193a, through recruitment of EZH2, and by a complex ceRNA mechanism in ovarian cancer cell lines. Importantly, cell line and animal experiments both confirmed that E2F6 promotes ovarian cancer stemness, whereas E2F6 or EZH2 depletion derepressed miR‐193a, which opposes cancer stemness, by alleviating DNA methylation and repressive chromatin. Finally, 118 ovarian cancer patients with miR‐193a promoter hypermethylation had poorer survival than those without hypermethylation. These results suggest that anAbstract : Ovarian cancer is the most lethal cancer of the female reproductive system. In that regard, several epidemiological studies suggest that long‐term exposure to estrogen could increase ovarian cancer risk, although its precise role remains controversial. To decipher a mechanism for this, we previously generated a mathematical model of how estrogen‐mediated upregulation of the transcription factor, E2F6, upregulates the ovarian cancer stem/initiating cell marker, c‐Kit, by epigenetic silencing the tumor suppressor miR‐193a, and a competing endogenous (ceRNA) mechanism. In this study, we tested that previous mathematical model, showing that estrogen treatment of immortalized ovarian surface epithelial cells upregulated both E2F6 and c‐KIT, but downregulated miR‐193a . Luciferase assays further confirmed that microRNA‐193a targets both E2F6 and c‐Kit . Interestingly, ChIP‐PCR and bisulphite pyrosequencing showed that E2F6 also epigenetically suppresses miR‐193a, through recruitment of EZH2, and by a complex ceRNA mechanism in ovarian cancer cell lines. Importantly, cell line and animal experiments both confirmed that E2F6 promotes ovarian cancer stemness, whereas E2F6 or EZH2 depletion derepressed miR‐193a, which opposes cancer stemness, by alleviating DNA methylation and repressive chromatin. Finally, 118 ovarian cancer patients with miR‐193a promoter hypermethylation had poorer survival than those without hypermethylation. These results suggest that an estrogen‐mediated E2F6 ceRNA network epigenetically and competitively inhibits microRNA‐193a activity, promoting ovarian cancer stemness and tumorigenesis. Abstract : Estrogen‐mediated E2F6 competing endogenous network epigenetically and competitively inhibits microRNA‐193a activity, promoting ovarian cancer stemness and tumorigenesis. … (more)
- Is Part Of:
- Cancer science. Volume 110:Issue 3(2019)
- Journal:
- Cancer science
- Issue:
- Volume 110:Issue 3(2019)
- Issue Display:
- Volume 110, Issue 3 (2019)
- Year:
- 2019
- Volume:
- 110
- Issue:
- 3
- Issue Sort Value:
- 2019-0110-0003-0000
- Page Start:
- 1085
- Page End:
- 1095
- Publication Date:
- 2019-01-25
- Subjects:
- ceRNA -- E2F6 -- epigenetics -- miR‐193a -- ovarian cancer
Cancer -- Periodicals
Neoplasms -- Periodicals
Research -- Periodicals
Electronic journals
616.994005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1347-9032;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1349-7006 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cas.13920 ↗
- Languages:
- English
- ISSNs:
- 1347-9032
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.603000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11585.xml